GLP-1 analogue-induced weight loss does not improve obesity-induced AT dysfunction

What Was Tested

The paper reports a study of Liraglutide in the context of fat loss, obesity & body recomposition, published as a randomized controlled trial.

GLP-1 treatment may however also directly influence AT that expresses the GLP-1 receptor (GLP-1R).

Assessments included clinical characteristics and repeated subcutaneous abdominal AT biopsies.

Who Took Part

According to the abstract, 39 participants were involved.

By PubMed's age tags, the people studied were middle-aged adults and older adults, men only.

Among the 39 participants with Type 2 diabetes recruited, 30 age-matched participants were randomized to 4 months treatment with Liraglutide (n=22) or calorie restriction based on dietetic counselling (n=8).

How the Study Was Run

The design is described as randomized.

Because people in this Liraglutide study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

What Was Measured

Assessments included clinical characteristics and repeated subcutaneous abdominal AT biopsies.

The subject headings attached to it are Adiponectin, Adipose Tissue, Diabetes Mellitus, Type 2, Extracellular Matrix, Glucagon-Like Peptide 1, Hypoglycemic Agents and Inflammation.

Author keywords: Liraglutide, Type 2 diabetes, adipose tissue fibrosis, glucagon-like peptide-1 (GLP-1) analogue and obesity.

What This Means in Plain Language

The paper is a randomized study of Liraglutide in 39 participants in people with fat loss, obesity & body recomposition.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

The publication is from 2017 (Clinical science (London, England : 1979)), a journal based in England.

More context: the Liraglutide compound page, Fat loss, obesity & body recomposition research.